What is Danaher's market cap?

Danaher (DHR) has a market capitalization of $135.02B and trades on NYSE.

What is Danaher's revenue and profitability?

Danaher generated $24.8B in trailing twelve-month revenue with net income of $3.7B, representing a net margin of 14.9%. Gross margin stands at 58.9%, with free cash flow of $5.3B. These figures are based on the Q1 2026 filing.

Who are Danaher's competitors?

Danaher's key competitors include Agilent Technologies, Thermo Fisher Scientific, Revvity, Inc., and others. These companies compete in similar markets and product categories.

Who does Danaher partner with?

Danaher's notable partners include U.S. Food and Drug Administration.

What subsidiaries does Danaher have?

Danaher's subsidiaries include Cytiva, Pall Corporation, Beckman Coulter, and others.

Where is Danaher headquartered?

Danaher is headquartered in United States of America and employs approximately 63,000 people. It has been publicly traded since 1978.

Danaher

DHR

Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services.

Market cap

$135.02B-7.2%

Revenue$24.8B+4.0%

Net income$3.7B-2.0%

Free cash flow$5.3B+7.9%

EPS (diluted)$5.17+0.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 21, 2026

Revenue$6.0BMiss by $30.6M EPS$2.06Beat by $0.12

Read the full report

Next report

Jul 21, 2026 (In 1 week)

Revenue estimate$6.1B

EPS estimate$1.83

Financials

Q1 2026

Income statement

See full

Revenue$6.0B+3.7%

Gross profit$3.6B+2.3%

Operating income$1.3B+5.5%

Net income$1.0B+7.9%

EPS (diluted)$1.45+9.8%

Balance sheet

See full

Cash & equivalents$5.7B+186%

Total debt$19.7B+12.0%

Total equity$52.9B+4.1%

Total assets$83.5B+5.6%

Cash flow

See full

Operating cash flow$1.3B+1.8%

CapEx$237.0M-3.3%

Free cash flow$1.1B+2.9%

Valuation & ratios

Valuation

See full

Market cap$137.44B-7.2%

Enterprise value$151.42B-7.5%

P/E37.3×-6.1×

P/S5.6×-0.6×

Profitability

See full

Gross margin58.9%-0.8pp

Operating margin19.2%-1.0pp

Net margin14.9%-0.9pp

FCF margin21.4%+0.8pp

Returns & leverage

See full

Return on equity7.1%-0.1pp

Debt / equity0.4×0.0×

Current ratio1.9×+0.4×

Segments

By geography

See full

North America$2.5B-4.0%

High-growth markets$1.6B+5.7%

Western Europe$1.6B+16.4%

Other developed markets$284.0M+2.2%

By product

See full

Recurring revenue$5.0B+4.5%

Nonrecurring revenue$920.0M-0.5%

By segment

See full

Biotechnology$1.8B+11.5%

Competitors

By market cap

Thermo Fisher Scientific$191.99B+18.9%

Danaher$137.44B-5.2%

Agilent Technologies$37.0B+8.1%

Revvity$12.5B+5.1%

TEC

Bio-Techne$11.0B+32.0%

Bio-Rad Laboratories$7.8B+14.8%

Dyadic International$38.6M+36.6%

Harvard Bioscience$29.9M+44.1%

By revenue growth

Agilent Technologies+9.1%

Revvity+4.8%

Danaher+4.0%

Thermo Fisher Scientific+2.4%

Bio-Rad Laboratories+1.9%

TEC

Bio-Techne+0.2%

By net margin

Agilent Technologies19.55%+2.0pp

Thermo Fisher Scientific15.19%+0.4pp

Danaher14.89%-0.9pp

TEC

Bio-Techne10.89%-0.7pp

Revvity8.26%-2.1pp

Bio-Rad Laboratories6.52%+91.7pp

Profile

Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through a decentralized model of over 15 operating companies, unified by the Danaher Business System (DBS) to drive continuous improvement in biotechnology, life sciences, and diagnostics. Its value proposition centers on accelerating the power of science to improve human health through a high level of recurring revenue from consumables and services.

Competitive position

Danaher holds leadership positions across its three core segments, leveraging its proprietary Danaher Business System (DBS) to maintain high margins and operational efficiency.

GeographiesNorth America, Europe, Asia, High-growth markets

Customer segmentsHealthcare providers, Academic and research institutions, Pharmaceutical and biotech companies

Business modelRazor-and-blade, Direct sales, Manufacturing, Recurring revenue

SuppliersMetallic-based components, Electronic components, Chemical raw materials, Plastics and petroleum-based products, OEM product suppliers

CustomersHospitals and clinical laboratories, Biopharmaceutical manufacturers, Academic research universities, Governmental healthcare entities

CountryUnited States of America

Listed1978

Employees63.0K

CEORainer Blair

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitedanaher.com

FilingsSEC EDGAR

Ask your AI about Danaher.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Danaher's market cap?: Danaher (DHR) has a market capitalization of $135.02B and trades on NYSE.
What is Danaher's revenue and profitability?: Danaher generated $24.8B in trailing twelve-month revenue with net income of $3.7B, representing a net margin of 14.9%. Gross margin stands at 58.9%, with free cash flow of $5.3B. These figures are based on the Q1 2026 filing.
Who are Danaher's competitors?: Danaher's key competitors include Agilent Technologies, Thermo Fisher Scientific, Revvity, Inc., and others. These companies compete in similar markets and product categories.
Who does Danaher partner with?: Danaher's notable partners include U.S. Food and Drug Administration.
What subsidiaries does Danaher have?: Danaher's subsidiaries include Cytiva, Pall Corporation, Beckman Coulter, and others.
Where is Danaher headquartered?: Danaher is headquartered in United States of America and employs approximately 63,000 people. It has been publicly traded since 1978.